Changes of plasma endothelin-1 (ET-1) and calcitonin gene related peptide (CGRP) of calcium dobesilate in treatment of diabetic retinopathy

Abstract

Objective To observe the changes of plasma endothelin-1 (ET-1) and calcitonin gene related peptide (CGRP) of calciurn dobesilate in treatment of diabetic retinopathy (DR). Methods This is a self-control trial. Plasma ET-1 and CGRP concentrations were measured with RIA in 100 patients with DR received calcium dobesilate (pretherapy, post-treatment: 2w, 1m, 3m and 6m). Results The content of plasma ET-1 were 186.15±43.89, 153.82±39.54, 121.27±38.45, 72.61±30.24 and 71.89±24.37ng/L at pretherapy and post-treatment (2w, 1m, 3m, 6m), respectively; that of plasma CGRP were 46.37±13.28, 43.42±12.78, 59.65±15.72, 68.87±25.36 and 67.91±24.75ng/L. After receiving the treatment with calcium dobesilate, the content of plasma ET-1 decreased and CGRP increased gradually. Conclusions Plasma ET-1 and CGRP play an important role in the whole patho-physiologic process in the DR treatment with calcium dobesilate, and measurement of their plasma concentrations may predict the curative effect on the DR follow-up. Key words: Calcium dobesilate; Diabetic retinopathy; Endothelin-1; Calcium gene related peptide